Highlights of the American College of Rheumatology 2010 Annual Scientific Meeting
The Latest Treatment Advances for Lupus
Treatment May Prevent Neonatal Lupus
The Brain and Lupus: 2010 Update
Risk of Some Cancers Double in Lupus
Assessing the Cost of Lupus
From the Lab to the Clinic: Lessons Learned About Lupus
ALR-Supported Research Focus of Plenary Session
Treatment May Help Prevent Neonatal Lupus
Exciting news for women at risk of delivering a child with neonatal lupus. A study presented at the ACR meeting found that women who took hydroxychloroquine (Plaquenil®) during their pregnancy reduced their risk of having a child with the cardiac form of the disease by 75% and the risk of any form of the disease (cardiac or cutaneous) by 44%.xvi
The study assessed the outcomes of 24 pregnancies in 22 women, 9 of whom had lupus and most of whom had who had anti-SSA/Ro antibodies, a major risk factor for neonatal lupus. These women had all had a child with either cardiac or cutaneous neonatal lupus, which increased their risk of having another child with the disease tenfold. The women took hydroxychloroquine 6 weeks before getting pregnant and throughout their pregnancy. While the expected rate of having another baby with cardiac neonatal lupus was about 17.2% in women who had given birth to a child with the disease, and 13% in women who had given birth to a child with cutaneous neonatal lupus, just one baby was born with cardiac neonatal disease (to a woman who had previously delivered a baby with cutaneous neonatal lupus), for a recurrence/occurrence rate of just 4.2%.
Key point: Using hydroxychloroquine before and during your pregnancy may reduce the risk of delivering a baby with cardiac neonatal lupus (which can be fatal for the baby).
More information about lupus and treatment advances can be found by visiting www.lupusresearch.org.
The 2010 American College of Rheumatology Meeting Special Report was made possible in part by generous support from Biogen Idec, Genentech and Johnson & Johnson.
©2010 Alliance for Lupus Research. All Rights Reserved.
Contents herein may not be reproduced, republished or distributed without the prior written permission of the Alliance for Lupus Research. To request permission to reproduce, republish or distribute any part of this report, contact us at 212-218-2840 or email email@example.com.